Mylan crafting new EpiPen sales model as it pushes past pricing mess

Mylan's EpiPen
Mylan is working to grow EpiPen's reach by helping restaurants and other public places get stocked up.

During Mylan’s EpiPen pricing controversy, CEO Heather Bresch blamed “middlemen” for more than half of EpiPen’s cost. Now the company is looking to cut them out while also eyeing a lucrative new sales avenue for the company’s key product.

Mylan has been lobbying for “entity prescription” legislation to allow public gathering places such as hotels, college campuses and parks to purchase the epinephrine injectors and keep them available in case of emergency.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

The company also has plans to offer EpiPens directly with its own pharmacy and avoid pharma middlemen, Bloomberg reports. According to Mylan’s website, the company set up Mylan On Location “to help businesses, organizations and institutions offer immediate care in emergency situations.” EpiPen is the first product available through the program.

By offering its product directly and cutting out distributors, Mylan can offer the market a significant discount while making the same profit, Michael Rea, CEO of Rx Savings Solutions, told the news service.

“It’s this kind of disruption in the pharmaceutical pricing model that we’re ripe for,” pharmacist Brad Arthur told the publication.

During Mylan’s EpiPen pricing defense, CEO Heather Bresch placed some of the blame on the supply chain, arguing that pharma “middlemen” account for more than half of EpiPen’s cost.

Things have been tough for Mylan since lawmakers placed the company’s key product in their watchdog crosshairs. Over several months, countless news reports highlighted multiple price hikes and a Medicaid misclassification that cost the company $465 million to settle with the DOJ. Last month, Mylan said it would lay off less than 10% of its global workforce, potentially translating to thousands of jobs on the chopping block.

To expand EpiPen’s reach, Mylan has been supporting “public entity legislation” to allow public places to purchase the lifesaving injections, Bresch said at a 2015 conference. “Really anywhere you are congregating there should be access to an EpiPen,” she added. At least 28 states now have such laws.

The strategy runs similar to Mylan’s partnership with Disney, struck back in 2014, enabling the entertainment company to keep EpiPens stocked at its theme parks and cruise ships.

In response to the pricing firestorm, the company also increased its access programs and rolled out an authorized generic at half the price, which hit shelves last month.

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

BMS is pricing Zeposia at the wholesale acquisition cost of $86,000, lower than the tag on Novartis' in-class rival Mayzent.